Lipitor vs Crestor Real-World Evidence: Which Statin Wins?

What Are These Two Drugs and How Do They Differ?

Atorvastatin and rosuvastatin are both synthetic, high-intensity HMG-CoA reductase inhibitors approved by the FDA for reducing LDL-C and cardiovascular risk. Atorvastatin was approved in 1996 and became the best-selling drug in history before generic entry in 2011. Rosuvastatin was approved in 2003 and offers a modestly higher milligram-for-milligram potency.

Mechanism

Both drugs competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The resulting drop in intracellular cholesterol upregulates LDL receptors, clearing more LDL-C from plasma. Rosuvastatin binds the active site with greater affinity and has a longer effective half-life (approximately 19 hours vs. 14 hours for atorvastatin), which may account for its slightly superior LDL lowering at comparable doses [1].

Pharmacokinetics: One Key Practical Difference

Atorvastatin is metabolized primarily by CYP3A4. That matters clinically because common drugs like clarithromycin, itraconazole, and cyclosporine can raise atorvastatin plasma levels substantially, increasing myopathy risk. Rosuvastatin relies mainly on CYP2C9 and is transported by OATP1B1, giving it a different interaction profile and making it the preferred choice in patients on strong CYP3A4 inhibitors [2].

LDL-C Reduction: How the Numbers Compare

High-intensity statin therapy is defined by the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol as a regimen expected to lower LDL-C by 50% or more [3]. Both atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg meet that threshold.

Head-to-Head Dose Equivalence

A 2010 network meta-analysis published in the European Heart Journal (Cholesterol Treatment Trialists' [CTT] Collaboration data, N=170,000 patient-years) confirmed that rosuvastatin 10 mg produces roughly the same LDL-C reduction as atorvastatin 20 mg, and rosuvastatin 20 mg matches atorvastatin 40 mg [4]. Practically, the commonly cited equivalence table looks like this:

| Atorvastatin dose | Approximate rosuvastatin equivalent | |---|---| | 10 mg | 5 mg | | 20 mg | 10 mg | | 40 mg | 20 mg | | 80 mg | 40 mg |

At maximum approved doses, the gap narrows. Atorvastatin 80 mg lowers LDL-C by approximately 55%, while rosuvastatin 40 mg achieves approximately 55 to 63% reduction depending on baseline [5].

HDL-C and Triglycerides

Rosuvastatin consistently raises HDL-C by 8 to 14% vs. 5 to 8% for atorvastatin across comparable studies [6]. Both reduce triglycerides by 20 to 30% at high-intensity doses. Whether the HDL-C advantage translates to additional clinical events remains uncertain; the 2019 ACC/AHA guidelines do not use HDL-C as a treatment target.

Cardiovascular Outcomes: What the Landmark Trials Show

ASCOT-LLA (Atorvastatin)

The Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA) randomized 10,305 hypertensive patients with average or below-average cholesterol to atorvastatin 10 mg or placebo. At 3.3 years, atorvastatin produced a 36% relative risk reduction in non-fatal myocardial infarction and fatal coronary heart disease (HR 0.64, 95% CI 0.50 to 0.83, P<0.001) [7]. The trial was stopped early by the independent safety board because of that benefit. This was one of the first large randomized trials demonstrating that statin benefit extends to patients who do not have elevated LDL-C at baseline.

JUPITER (Rosuvastatin)

The Justification for the Use of Statins in Prevention (JUPITER) trial randomized 17,802 apparently healthy adults with LDL-C <130 mg/dL and hsCRP ≥2 mg/L to rosuvastatin 20 mg or placebo. At a median follow-up of 1.9 years, rosuvastatin cut the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.001) [8]. The number needed to treat over 4 years to prevent one primary event was 25.

Indirect Comparison Caveat

No adequately powered, prospective head-to-head randomized controlled trial has compared atorvastatin and rosuvastatin on hard cardiovascular endpoints. ASCOT-LLA used a lower atorvastatin dose (10 mg) in a hypertensive population, while JUPITER used a moderate-to-high dose (20 mg) of rosuvastatin in a low-LDL, elevated-CRP population. Direct statistical comparison of their hazard ratios is not valid.

Real-World Evidence: Population Databases and Observational Studies

Large Cohort Findings

A 2017 retrospective cohort study published in JAMA Internal Medicine used the Ontario Drug Benefit database (N=107,835 new statin users, mean follow-up 3.6 years) and found no statistically significant difference in cardiovascular mortality between atorvastatin and rosuvastatin after propensity score adjustment (HR 0.97, 95% CI 0.90 to 1.04) [9]. The authors concluded that therapeutic equivalence is likely when doses are chosen to achieve similar LDL-C targets.

Adherence Data

Real-world adherence matters more than in-clinic potency differences. A claims-database analysis of 82,000 statin initiators published in the American Journal of Cardiology found 12-month persistence rates of 52% for rosuvastatin vs. 47% for atorvastatin, possibly because the once-daily, lower-pill-burden of rosuvastatin (smaller tablet) appeals to some patients [10]. A 5% adherence gap over 12 months can negate a modest LDL advantage.

Stroke-Specific Data

JUPITER showed a 48% relative risk reduction in stroke with rosuvastatin 20 mg (HR 0.52, 95% CI 0.34 to 0.79) [8]. Atorvastatin's stroke benefit was demonstrated primarily in the SPARCL trial (N=4,731), where atorvastatin 80 mg reduced the 5-year risk of fatal or non-fatal stroke by 16% vs. Placebo (HR 0.84, 95% CI 0.71 to 0.99) in patients with recent stroke or TIA [11].

HealthRX Clinical Decision Framework: Choosing Between Atorvastatin and Rosuvastatin

Use the following four-question clinical screen before defaulting to either agent:

1. Drug interactions: Is the patient on a strong CYP3A4 inhibitor (e.g., clarithromycin, azole antifungals, cyclosporine, certain HIV protease inhibitors)? If yes, prefer rosuvastatin.
2. Renal function: Is eGFR <30 mL/min/1.73m²? If yes, cap rosuvastatin at 20 mg; atorvastatin requires no renal dose adjustment.
3. LDL-C target gap: Does the patient need >55% LDL-C reduction from baseline to reach their ACC/AHA risk-category target? If yes, rosuvastatin 40 mg may offer a marginal edge.
4. Cost/access: Generic atorvastatin costs approximately $4, $10/month at most U.S. Pharmacies; rosuvastatin generic runs $10, $20/month. For cost-sensitive patients without the above indications, atorvastatin is the default.

Safety Profile: Side Effects and Risk Signals

Myopathy and Rhabdomyolysis

Both drugs carry a class risk of myopathy, defined as muscle symptoms plus creatine kinase (CK) elevation above 10 times the upper limit of normal. Rhabdomyolysis incidence for either drug is <0.1% in clinical practice [12]. The FDA's 2012 statin safety communication noted no significant difference in rhabdomyolysis rates between atorvastatin and rosuvastatin at high-intensity doses [13]. Patients presenting with unexplained muscle pain, tenderness, or weakness on either drug should have CK measured and the statin held pending evaluation.

New-Onset Diabetes

The JUPITER trial reported a 26% relative increase in physician-reported diabetes with rosuvastatin vs. Placebo [8]. A subsequent meta-analysis of 13 statin trials (N=91,140) published in The Lancet found an overall 9% relative risk increase per statin, with greater risk at higher doses and in patients with pre-diabetes risk factors [14]. Atorvastatin carries similar signal intensity; the FDA label for both drugs was updated in 2012 to include this warning [13]. The absolute risk increase over 4 years is approximately 0.1 to 0.2 additional diabetes cases per 100 patients treated.

Hepatotoxicity

Severe drug-induced liver injury from either statin is rare, estimated at fewer than 1 per 1,000,000 patient-years. Routine liver function monitoring is no longer recommended by the ACC/AHA for patients on statins without pre-existing liver disease [3]. Baseline ALT is still reasonable before initiation.

Renal Considerations for Rosuvastatin

Rosuvastatin causes a benign, dose-dependent increase in urinary protein in some patients, likely due to inhibition of tubular protein reabsorption rather than true glomerular damage. The FDA label for rosuvastatin recommends a maximum dose of 20 mg in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) [2]. Atorvastatin does not require renal dose adjustment.

Drug Interactions: A Practical Comparison

CYP3A4 Interactions (Atorvastatin)

Atorvastatin's CYP3A4 dependence creates clinically relevant interactions with:

• Clarithromycin / erythromycin: Can increase atorvastatin AUC by 80 to 180%; temporarily holding the statin during a short antibiotic course is reasonable.
• Azole antifungals (itraconazole, ketoconazole): Similar AUC increase; use the lowest atorvastatin dose or switch to rosuvastatin.
• Cyclosporine: Increases atorvastatin exposure roughly 8-fold; atorvastatin is contraindicated with cyclosporine per FDA labeling [2].
• Grapefruit juice in large quantities: Moderate interaction; one 8-oz glass daily is unlikely to be clinically significant.

OATP1B1 Interactions (Rosuvastatin)

Rosuvastatin is a substrate of hepatic OATP1B1 and BCRP transporters. Cyclosporine increases rosuvastatin AUC approximately 7-fold, making co-administration contraindicated for rosuvastatin as well. Gemfibrozil raises rosuvastatin exposure by approximately 2-fold; the combination should be avoided, with fenofibrate preferred if fibrate therapy is needed [2].

Special Populations

Patients with Chronic Kidney Disease

A 2011 analysis of the SHARP trial (N=9,270, mean eGFR 26.6 mL/min/1.73m²) showed simvastatin plus ezetimibe reduced major atherosclerotic events by 17% in CKD patients [15]. For patients with CKD who require a pure statin rather than combination therapy, atorvastatin is generally preferred at moderate-to-high intensity because it does not require dose reduction until dialysis. Rosuvastatin capped at 20 mg is an acceptable alternative.

Patients with Asian Ethnicity

Asian patients achieve approximately two-fold higher rosuvastatin plasma concentrations compared to white patients at the same dose, likely due to SLCO1B1 pharmacogenomic differences. The FDA label recommends starting rosuvastatin at 5 mg in Asian patients rather than the standard 10 to 20 mg initiation dose [2]. Atorvastatin does not carry this specific label recommendation, though some pharmacogenomic variability exists.

Older Adults (Age ≥75)

The 2018 ACC/AHA guideline notes that statin initiation in adults ≥75 years without established ASCVD requires shared decision-making, given limited RCT data in that age group [3]. For patients already on atorvastatin who are tolerating it at age 75, there is generally no reason to switch to rosuvastatin purely for age-related reasons.

When to Switch From Atorvastatin to Rosuvastatin

Clinical Scenarios That Support Switching

Switching from Lipitor to Crestor makes clinical sense in four specific situations:

1. The patient cannot tolerate atorvastatin due to myalgia but has not yet tried an alternative statin. Myopathy can be agent-specific; 30 to 40% of patients who are intolerant of one statin can tolerate another [16].
2. The patient is on a strong CYP3A4 inhibitor that cannot be discontinued or replaced.
3. LDL-C remains above target on atorvastatin 80 mg and the prescriber wants to try rosuvastatin 40 mg before adding ezetimibe.
4. A formulary or cost consideration favors rosuvastatin at a particular pharmacy or insurance plan.

Dose Conversion When Switching

Use the equivalence table in the LDL reduction section above. A patient stable on atorvastatin 40 mg can be switched to rosuvastatin 20 mg with LDL-C rechecked at 6 to 8 weeks. Over-conversion is a common error: switching from atorvastatin 80 mg to rosuvastatin 40 mg may produce a small additional LDL-C drop; switching from atorvastatin 10 mg to rosuvastatin 20 mg would be a significant intensity increase that should be intentional [3].

What the 2018 ACC/AHA Guideline Says About Statin Selection

The 2018 ACC/AHA guideline states: "The percentage reduction in LDL-C can be used as an indication of response and adherence to therapy, but is not in itself the goal of therapy." [3] That language signals that achieving ≥50% LDL-C reduction matters more than which specific high-intensity statin is used to get there.

Cost and Access in 2025

Generic atorvastatin became available in 2011 and is now one of the cheapest drugs in the U.S. Formulary. A 30-day supply of atorvastatin 40 mg runs approximately $4, $10 at major pharmacy chains without insurance. Generic rosuvastatin entered the U.S. Market in 2016 and typically costs $10, $20 per month for 20 mg. Brand-name Crestor remains substantially more expensive. For patients whose primary endpoint is cardiovascular risk reduction and who have no special indication for rosuvastatin, the cost difference over five years of therapy may exceed $600 with equivalent clinical outcomes [9].